After treatment initiation with liraglutide 3.0 mg, it is recommended that, if a patient has not lost at least 4% of their baseline body weight after 16 weeks, the treatment should be discontinued because it is unlikely that significant weight loss will be achieved with the medication after this time point [21]
It also requires physician signature and date signed in dd/mmm/yyyy format, and validates the signed date is not in the future
It is not FDA-approved for weight loss: its clinical development was halted after Phase 2b, so any use is off-label and should be supervised by a licensed provider
Patients commonly report improved skin elasticity, better sleep quality, increased energy, enhanced recovery from exercise, and improved body composition
Baltimore: Williams & Wilkins